调查发现,Ozempic 用户减少了在超市购买零食 
Ozempic Users Slash Snack Buying At Supermarkets, Survey Finds 

原始链接: https://www.zerohedge.com/medical/ozempic-users-slash-snack-buying-supermarket-survey-finds

最近的一份市场研究报告显示,服用被称为 GLP-1 药物的减肥药物的家庭显着减少了在超市的购物支出。 Numerator 的一项新研究发现,目前服用 GLP-1 药物的家庭每月的支出比未开这种药物的家庭少 6-9%。 下降主要体现在零食、糕点和冰淇淋上,而购买这些药品的家庭则表示购买水果、蔬菜和酸奶等低脂乳制品的数量有所增加。 此外,12.3%的美国家庭使用GLP-1,高于10月份的数字。 这种变化可能是由于人们对抗肥胖药物的认识不断增强,因为越来越多的人选择自费支付这些治疗费用。 结果,随着消费者偏好转向更健康的选择,主要食品零售商和制造商面临损失。 这一趋势引发了关于与肥胖药物相关的潜在下游风险的争论,包括银行高管预测的衣柜更换周期。 然而,这项研究强调了生活方式的改变如何能够显着节省成本,这表明人们不一定需要昂贵的处方药来达到健康的体重。 根据其他专家的观点,植物油的消费也可能导致肥胖水平。

相关文章

原文

America's anti-obesity craze, courtesy of GLP-1-based weight-loss drugs such as Wegovy and Mounjaro, produced by Novo Nordisk and Eli Lilly, continues to create anxiety among the food-industrial complex after a new study cited by Morgan Stanley shows households on the weight-loss drugs are spending less at the supermarket. 

Market research provider Numerator's new survey shows households using GLP-1 drugs decreased monthly supermarket spending by 6% to 9% versus non-GLP-1 households. 

Many GLP-1 households increased purchases of fish, vegetables, and yogurt while sales of snacks, pastries, and ice cream fell. 

MS noted the Numerator survey from January used data from more than 90,000 households, with 12.3% of households indicating they were on GLP-1 drugs, up from 11.4% in October. 

The main driver of GLP-1 has been weight-loss treatment, and MS pointed out more and more consumers are paying out of pocket for the drug. 

Last year, we asked if America's anti-obesity craze courtesy of GLP-1 drugs would trigger a "food revolution." And quickly, Wall Street analysts took notice by downgrading some junk food companies, such as Krispy Kreme, citing GLP-1 impacts

Last August, Walmart CEO Doug McMillon said shoppers who pick up appetite-suppressing medications at in-store pharmacies are spending less money on food:

"We still expect food, consumables, and health and wellness primarily due to the popularity of some GLP-1 drugs to grow as a percent of total in the back half." 

And portion sizes at Thanksgiving 2023 were much smaller for the folks who could cough up $1,000 per month for the weight-loss drugs. 

In a separate note, Bank of America analyst Geoff Meacham recently said weight loss will trigger a "wardrobe replacement cycle." 

Despite the decline in GLP-1 mentions on earnings calls... 

Wall Street is still piling into Goldman's GLP-1 Obesity drug basket to capitalize on slimming down Americans while trimming companies with potential downstream risks related to obesity drugs, as indicated by the Goldman Sachs Global HLC GLP Risk index. 

Make America Skinny (again). 

Hmm. 

Maybe consumers should ditch vegetable oils.

联系我们 contact @ memedata.com